Business Wire

TAMPERE-UNIVERSITY

25.5.2021 07:02:08 CEST | Business Wire | Press release

Share
Reusing Reclaimed Precast Concrete Elements in New Buildings – Tampere University, Finland, Coordinates a Major International Project

Concrete is widely used as a construction material, but it has a substantial environmental impact. When a building is demolished, what happens to all the concrete? Tampere University, Finland, is coordinating the new international ReCreate project, which aims to discover how used concrete elements can be deconstructed without damaging them and reused in new buildings – and to turn the process into a profitable business. The four-year project has received €12.5 million of funding under the EU’s Horizon 2020 programme.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005850/en/

Concrete has been the world’s most commonly used building material for at least half a century. It accounts for the majority of both construction materials and demolition waste. In Europe, concrete buildings are commonly constructed using precast concrete elements. If the old elements could be reused instead of manufacturing new ones, it would bring major benefits for the environment.

“By reusing concrete elements, we can save an enormous amount of energy and raw materials,” says Satu Huuhka , adjunct professor at the Faculty of Built Environment at Tampere University, who leads the ReCreate project.

The recently launched international ReCreate project (2021–2025) coordinated by Tampere University seeks to find new uses for the concrete elements of condemned buildings in the construction of new buildings. The four-year project has received funding under the European Union’s Horizon 2020 call, and it seeks solutions for reusing construction and demolition waste. The project has an overall budget of €12.5 million. The project involves universities and regional company clusters in four countries: Finland, Sweden, the Netherlands, and Germany. The communications partner is the Croatia Green Building Council. All the country clusters will carry out their own pilot projects where they deconstruct precast concrete elements intact and reuse them in a new building.

“We are specifically looking to reuse the concrete elements as a whole, not as a raw material for something new,” Huuhka points out.

Tapping into Finland’s world-class expertise

Researchers at the Faculty of Built Environment have been carrying out ground-breaking research into the circular economy in the construction sector for a decade. In addition, long-term research on renovation and the lifecycle engineering of structures provides a solid foundation for the development of quality assurance procedures that will ensure the safety and integrity of the reused elements. This time, the researchers are set to explore not only the technical implementation of the solutions but also the business perspective.

“There are many questions to be answered. How do we deconstruct the elements from buildings without damaging them? How do we assess their structural integrity? How do we recertify the salvaged elements and turn them into a product that meets building code requirements? Since the elements are not of uniform quality, how can we turn this into a viable business? We must also consider the social aspects: does the process require new skills or new ways of working?” Huuhka asks.

Tampere University researchers will also bring to the project their specialist expertise in circular economy business models, building regulations and law, and occupational sociology. The Finnish country cluster comprises Tampere University, the construction company Skanska, the demolition company Umacon, the precast concrete company Consolis Parma, the engineering and consultancy company Ramboll, the architecture firm Liike Oy Arkkitehtistudio and the City of Tampere.

Tampere University

The multidisciplinary Tampere University is the second largest university in Finland. The spearheads of our research and learning are technology, health and society. The University is committed to addressing the greatest challenges that are facing our society and creating new opportunities. Almost all the internationally recognised fields of study are represented at the University. Together Tampere University and Tampere University of Applied Sciences comprise the Tampere Universities community made up of more than 30,000 students and close to 5,000 employees. www.tuni.fi/en

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release

Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release

Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye